

Fangxin Hong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1460685/publications.pdf>

Version: 2024-02-01

97
papers

5,966
citations

117453

34
h-index

74018

75
g-index

100
all docs

100
docs citations

100
times ranked

9055
citing authors

#	ARTICLE	IF	CITATIONS
1	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	0.8	9
2	Transitioning from Heparin to Saline Locks for Central Venous Access Devices in Oncology: An Evidence-Based Practice Approach. <i>Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique</i> , 2022, 32, 286-293.	0.1	1
3	Decision support for men with prostate cancer: Concordance between treatment choice and tumor risk. <i>Cancer</i> , 2021, 127, 203-208.	2.0	2
4	Informing models of cancer genetics care in the era of multigene panel testing with patient-tailored recommendations. <i>Journal of Genetic Counseling</i> , 2021, 30, 268-282.	0.9	5
5	Effect of Capivasertib in Patients With an <i>AKT1 E17K</i> -Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.	3.4	49
6	Reply to What is a good medical choice?. <i>Cancer</i> , 2021, 127, 1935-1936.	2.0	0
7	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	1.5	4
8	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021, 11, 1952-1969.	7.7	87
9	Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study. <i>BMC Cancer</i> , 2021, 21, 236.	1.1	11
10	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
11	Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 408-418.	0.6	16
12	Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. <i>Blood</i> , 2021, 138, 815-815.	0.6	0
13	Self-Reported Severity, Characteristics, and Functional Limitations of Chemotherapy-Induced Peripheral Neuropathy. <i>Pain Management Nursing</i> , 2021, , .	0.4	3
14	The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 377-385.	1.1	3
15	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2020, 7, e660-e670.	2.2	86
16	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	0.8	102
17	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	3.2	16
18	Threats of Bots and Other Bad Actors to Data Quality Following Research Participant Recruitment Through Social Media: Cross-Sectional Questionnaire. <i>Journal of Medical Internet Research</i> , 2020, 22, e23021.	2.1	109

#	ARTICLE	IF	CITATIONS
19	Health behaviours and beliefs in individuals with familial pancreatic cancer. <i>Familial Cancer</i> , 2019, 18, 457-464.	0.9	4
20	The effect of a lifestyle risk reduction intervention on lifestyle adherence and health-related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomes. <i>Psycho-Oncology</i> , 2019, 28, 920-923.	1.0	0
21	Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support. <i>Urology Practice</i> , 2019, 6, 93-99.	0.2	7
22	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
23	Impact of Electronic Self-Assessment and Self-Care Technology on Adherence to Clinician Recommendations and Self-Management Activity for Cancer Treatment-Related Symptoms: Secondary Analysis of a Randomized Controlled Trial. <i>JMIR Cancer</i> , 2019, 5, e11395.	0.9	4
24	Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. <i>Psycho-Oncology</i> , 2018, 27, 1711-1718.	1.0	13
25	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
26	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47
27	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole Continuation (BIONIC) Study. <i>Blood</i> , 2018, 132, 1615-1615.	0.6	1
28	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018, 132, 679-679.	0.6	13
29	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018, 132, 623-623.	0.6	1
30	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. <i>Blood</i> , 2018, 132, 4157-4157.	0.6	0
31	RankProd 2.0: a refactored bioconductor package for detecting differentially expressed features in molecular profiling datasets. <i>Bioinformatics</i> , 2017, 33, 2774-2775.	1.8	113
32	Psychosocial outcomes of an electronic self-report assessment and self-care intervention for patients with cancer: a randomized controlled trial. <i>Psycho-Oncology</i> , 2017, 26, 1866-1871.	1.0	20
33	HLA-Bw4-1-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 675.	2.2	18
34	Patient-reported symptom distress, and most bothersome issues, before and during cancer treatment. <i>Patient Related Outcome Measures</i> , 2016, Volume 7, 127-135.	0.7	20
35	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
36	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. <i>British Journal of Haematology</i> , 2016, 173, 867-875.	1.2	36

#	ARTICLE	IF	CITATIONS
37	Defining optimal initial therapy for primary CNS lymphoma. <i>Lancet Haematology</i> , 2016, 3, e206-e207.	2.2	3
38	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). <i>Cancer</i> , 2016, 122, 2996-3004.	2.0	31
39	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
40	Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). <i>Blood</i> , 2016, 128, 1106-1106.	0.6	34
41	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992.	0.6	5
42	Screening for Pain in the Ambulatory Cancer Setting: Is 0-10 Enough?. <i>Journal of Oncology Practice</i> , 2015, 11, 435-441.	2.5	4
43	A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG 3402. <i>British Journal of Haematology</i> , 2015, 170, 679-686.	1.2	19
44	Evaluation of the International Prognostic Score (IPS) and a Simpler Prognostic Score (IPS) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	1.2	54
45	Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. <i>Patient Preference and Adherence</i> , 2015, 9, 1587.	0.8	52
46	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	0.8	33
47	Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015, 170, 56-65.	1.2	50
48	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015, 126, 585-585.	0.6	25
49	Symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 188-194.	0.1	13
50	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq0 0 0 rgBT. Overlook 10 Tf 50		
51	Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. <i>Blood</i> , 2015, 126, 2702-2702.	0.6	0
52	Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). <i>Leukemia and Lymphoma</i> , 2014, 55, 768-772.	0.6	42
53	Electronic Self-Report Assessment for Cancer and Self-Care Support: Results of a Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 199-205.	0.8	171
54	The electronic self report assessment and intervention for cancer: promoting patient verbal reporting of symptom and quality of life issues in a randomized controlled trial. <i>BMC Cancer</i> , 2014, 14, 513.	1.1	56

#	ARTICLE	IF	CITATIONS
55	Risk Factors for Depression in Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 946-950.	2.0	35
56	Gene Expressionâ€‘Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	0.8	176
57	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , 2013, 160, 351-358.	1.2	19
58	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	0.8	256
59	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	1.2	111
60	The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1012-1021.	0.8	95
61	Subset of heat-shock transcription factors required for the early response of <i>Arabidopsis</i> to excess light. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14474-14479.	3.3	123
62	Run-In Phase III Trial Design With Pharmacodynamics Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1628-1633.	3.0	10
63	Incremental value in outcome prediction with gene expressionâ€‘based signatures in diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 121, 156-158.	0.6	20
64	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	0.6	117
65	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
66	Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma. <i>Blood</i> , 2013, 122, 507-507.	0.6	5
67	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome d'Adultes. <i>Blood</i> , 2013, 122, 3045-3045.	0.6	2
68	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90â€‘labeled Rituximab in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	0.8	86
69	Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 718-720.	0.6	26
70	Decision preparation, satisfaction and regret in a multi-center sample of men with newly diagnosed localized prostate cancer. <i>Patient Education and Counseling</i> , 2012, 88, 262-267.	1.0	66
71	A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).. <i>Blood</i> , 2012, 120, 2687-2687.	0.6	2
72	Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. <i>Blood</i> , 2012, 120, 3705-3705.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Metabolic sugar signal promotes Arabidopsis meristematic proliferation via G2. <i>Developmental Biology</i> , 2011, 351, 82-89.	0.9	63
74	Patient–provider communication data: linking process and outcomes in oncology care. <i>Cancer Management and Research</i> , 2011, 3, 311.	0.9	4
75	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011, 118, 1603-1603.	0.6	3
76	A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma â€œ a Correlative Study From the E2496 Intergroup Trial. <i>Blood</i> , 2011, 118, 430-430.	0.6	1
77	Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). <i>Blood</i> , 2011, 118, 1568-1568.	0.6	2
78	Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , 2011, 118, 87-87.	0.6	1
79	Incremental Value in Outcome Prediction with Molecular Signatures in Diffuse Large B-Cell Lymphoma,. <i>Blood</i> , 2011, 118, 3687-3687.	0.6	0
80	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstr�m Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1422-1428.	0.8	150
81	Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2010, 16, 1033-1041.	3.2	112
82	Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. <i>Blood</i> , 2010, 116, 416-416.	0.6	8
83	R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793. <i>Blood</i> , 2010, 116, 589-589.	0.6	7
84	Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up. <i>Leukemia and Lymphoma</i> , 2009, 50, 1632-1641.	0.6	4
85	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-mafâ€œmediated interactions with bone marrow stromal cells. <i>Blood</i> , 2009, 113, 4309-4318.	0.6	75
86	Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.. <i>Blood</i> , 2009, 114, 1671-1671.	0.6	8
87	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2009, 114, 2727-2727.	0.6	0
88	Rapid Synthesis of Auxin via a New Tryptophan-Dependent Pathway Is Required for Shade Avoidance in Plants. <i>Cell</i> , 2008, 133, 164-176.	13.5	928
89	Network Discovery Pipeline Elucidates Conserved Time-of-Dayâ€œSpecific cis-Regulatory Modules. <i>PLoS Genetics</i> , 2008, 4, e14.	1.5	474
90	Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2008, 112, 1010-1010.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Gene Transcriptional Activity Analysis in the 6q Region in Waldenstrom Macroglobulinemia (WM) Using ChIP-on-Chip Technology. <i>Blood</i> , 2008, 112, 628-628.	0.6	0
92	CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs). <i>Blood</i> , 2008, 112, 840-840.	0.6	1
93	Signals from Chloroplasts Converge to Regulate Nuclear Gene Expression. <i>Science</i> , 2007, 316, 715-719.	6.0	196
94	Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).. <i>Blood</i> , 2007, 110, 3420-3420.	0.6	14
95	Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.. <i>Blood</i> , 2007, 110, 4989-4989.	0.6	1
96	Different Plant Hormones Regulate Similar Processes through Largely Nonoverlapping Transcriptional Responses. <i>Cell</i> , 2006, 126, 467-475.	13.5	859
97	MOLECULAR MECHANISMS OF STEROID HORMONE SIGNALING IN PLANTS. <i>Annual Review of Cell and Developmental Biology</i> , 2005, 21, 177-201.	4.0	369